{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T21:35:25Z","timestamp":1783632925031,"version":"3.55.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"CNS Therapeutics, Inc."},{"name":"S. Jus\u00e9lius Foundation"},{"name":"University of Helsinki Research Foundation"},{"DOI":"10.13039\/501100004591","name":"CIMO","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004591","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Finnish Government Scholarship Pool"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurobiology of Disease"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.nbd.2016.07.008","type":"journal-article","created":{"date-parts":[[2016,7,17]],"date-time":"2016-07-17T00:52:30Z","timestamp":1468716750000},"page":"335-345","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"special_numbering":"C","title":["Developing therapeutically more efficient Neurturin variants for treatment of Parkinson's disease"],"prefix":"10.1016","volume":"96","author":[{"given":"Pia","family":"Runeberg-Roos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3960-2194","authenticated-orcid":false,"given":"Elisa","family":"Piccinini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Maija","family":"Penttinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kert","family":"M\u00e4tlik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Heikkinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satu","family":"Kuure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxim M.","family":"Bespalov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Per\u00e4nen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Garea-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eberhard","family":"Fuchs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikko","family":"Airavaara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisse","family":"Kalkkinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Penn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mart","family":"Saarma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nbd.2016.07.008_bb0005","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/cne.10689","article-title":"Intraputamenal infusion of GDNF in aged rhesus monkeys: distribution and dopaminergic effects","volume":"461","author":"Ai","year":"2003","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.nbd.2016.07.008_bb0010","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1042\/BJ20061747","article-title":"The major determinant of the heparin binding of glial cell-line-derived neurotrophic factor is near the N-terminus and is dispensable for receptor binding","volume":"404","author":"Alfano","year":"2007","journal-title":"Biochem. J."},{"key":"10.1016\/j.nbd.2016.07.008_bb0015","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.mce.2006.03.013","article-title":"Gene expression patterns for GDNF and its receptors in the human putamen affected by Parkinson's disease: a real-time PCR study","volume":"252","author":"B\u00e4ckman","year":"2006","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.nbd.2016.07.008_bb0020","article-title":"Clinical tests of neurotrophic factors for human neurodegenerative diseases, part 1: where have we been and what have we learned?","author":"Bartus","year":"2016","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.nbd.2016.07.008_bb0025","article-title":"Clinical tests of neurotrophic factors for human neurodegenerative diseases, part 2: where do we stand and where must we go next?","author":"Bartus","year":"2016","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.nbd.2016.07.008_bb0030","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/mds.23442","article-title":"Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains","volume":"26","author":"Bartus","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.nbd.2016.07.008_bb0035","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.neurobiolaging.2012.07.018","article-title":"Advancing neurotrophic factors as treatments for age-related neurodegenerative diseases: developing and demonstrating \u201cclinical proof-of-concept\u201d for AAV-neurturin (CERE-120) in Parkinson's disease","volume":"34","author":"Bartus","year":"2013","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.nbd.2016.07.008_bb0040","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1083\/jcb.201009136","article-title":"Heparan sulfate proteoglycan syndecan-3 is a novel receptor for GDNF, neurturin, and artemin","volume":"192","author":"Bespalov","year":"2011","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.nbd.2016.07.008_bb0045","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0896-6273(00)80514-0","article-title":"GFRalpha1 is an essential receptor component for GDNF in the developing nervous system and kidney","volume":"21","author":"Cacalano","year":"1998","journal-title":"Neuron"},{"key":"10.1016\/j.nbd.2016.07.008_bb0050","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1161\/01.ATV.9.1.21","article-title":"Molecular modeling of protein-glycosaminoglycan interactions","volume":"9","author":"Cardin","year":"1989","journal-title":"Arteriosclerosis"},{"key":"10.1016\/j.nbd.2016.07.008_bb0055","doi-asserted-by":"crossref","first-page":"27505","DOI":"10.1074\/jbc.M000306200","article-title":"Binding of GDNF and neurturin to human GDNF family receptor \u03b1 1 and 2. Influence of cRET and cooperative interactions","volume":"275","author":"Cik","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.nbd.2016.07.008_bb0060","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/(SICI)1520-6408(1999)24:3\/4<284::AID-DVG11>3.0.CO;2-X","article-title":"Neurturin: an autocrine regulator of renal collecting duct development","volume":"24","author":"Davies","year":"1999","journal-title":"Dev. Genet."},{"key":"10.1016\/j.nbd.2016.07.008_bb0065","doi-asserted-by":"crossref","first-page":"29377","DOI":"10.1074\/jbc.M004724200","article-title":"Unraveling the amino acid sequence crucial for heparin binding to collagen V","volume":"275","author":"Delacoux","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.nbd.2016.07.008_bb0070","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/nsb0697-435","article-title":"X-ray structure of glial cell-derived neurotrophic factor at 1.9\u00c5 resolution and implications for receptor binding","volume":"4","author":"Eigenbrot","year":"1997","journal-title":"Nat. Struct. Biol."},{"key":"10.1016\/j.nbd.2016.07.008_bb0075","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.expneurol.2005.03.006","article-title":"Efficient in vivo protection of nigral dopaminergic neurons by lentiviral gene transfer of a modified neurturin construct","volume":"195","author":"Fjord-Larsen","year":"2005","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.nbd.2016.07.008_bb0080","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/ana.20549","article-title":"Trophic factor distribution predicts functional recovery in parkinsonian monkeys","volume":"58","author":"Gash","year":"2005","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.nbd.2016.07.008_bb0085","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/nm850","article-title":"Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease","volume":"9","author":"Gill","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.nbd.2016.07.008_bb0090","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1006\/exnr.1999.7127","article-title":"Expression of neurturin, GDNF, and GDNF family-receptor mRNA in the developing and mature mouse","volume":"158","author":"Golden","year":"1999","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.nbd.2016.07.008_bb0095","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1006\/exnr.2000.7571","article-title":"Heparin coinfusion during convection-enhanced delivery (CED) increases the distribution of the glial-derived neurotrophic factor (GDNF) ligand family in rat striatum and enhances the pharmacological activity of neurturin","volume":"168","author":"Hamilton","year":"2001","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.nbd.2016.07.008_bb0100","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1006\/exnr.2000.7311","article-title":"Mammalian-cell-produced neurturin (NTN) is more potent than purified Escherichia coli-produced NTN","volume":"162","author":"Hoane","year":"2000","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.nbd.2016.07.008_bb0105","doi-asserted-by":"crossref","first-page":"4929","DOI":"10.1523\/JNEUROSCI.18-13-04929.1998","article-title":"Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons","volume":"18","author":"Horger","year":"1998","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2016.07.008_bb0110","doi-asserted-by":"crossref","first-page":"4686","DOI":"10.1523\/JNEUROSCI.20-12-04686.2000","article-title":"Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system","volume":"20","author":"Kirik","year":"2000","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2016.07.008_bb0115","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/mds.25344","article-title":"Trophic factor gene therapy for Parkinson's disease","volume":"28","author":"Kordower","year":"2013","journal-title":"Mov. Disord."},{"key":"10.1016\/j.nbd.2016.07.008_bb0120","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/384467a0","article-title":"Neurturin, a relative of glial-cell-line-derived neurotrophic factor","volume":"384","author":"Kotzbauer","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.nbd.2016.07.008_bb0125","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/ana.20737","article-title":"Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease","volume":"59","author":"Lang","year":"2006","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.nbd.2016.07.008_bb0130","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1126\/science.8493557","article-title":"GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons","volume":"260","author":"Lin","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.nbd.2016.07.008_bb0135","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S1474-4422(10)70254-4","article-title":"Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial","volume":"9","author":"Marks","year":"2010","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.nbd.2016.07.008_bb0140","doi-asserted-by":"crossref","first-page":"35164","DOI":"10.1074\/jbc.M802543200","article-title":"The structure of the glial cell line-derived neurotrophic factor-coreceptor complex: insights into RET signaling and heparin binding","volume":"283","author":"Parkash","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.nbd.2016.07.008_bb0145","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3109\/07853890.2012.663927","article-title":"Glial cell line-derived neurotrophic factor: characterization of mammalian posttranslational modifications","volume":"45","author":"Piccinini","year":"2013","journal-title":"Ann. Med."},{"key":"10.1016\/j.nbd.2016.07.008_bb0150","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jneumeth.2010.10.005","article-title":"Medium-throughput computer aided micro-island method to assay embryonic dopaminergic neuron cultures in vitro","volume":"194","author":"Planken","year":"2010","journal-title":"J. Neurosci. Methods"},{"key":"10.1016\/j.nbd.2016.07.008_bb0155","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1093\/glycob\/cwg046","article-title":"The binding of human glial cell line-derived neurotrophic factor to heparin and heparan sulfate: importance of 2-O-sulfate groups and effect on its interaction with its receptor, GFRalpha1","volume":"13","author":"Rickard","year":"2003","journal-title":"Glycobiology"},{"key":"10.1016\/j.nbd.2016.07.008_bb0160","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1080\/07853890701646256","article-title":"Neurotrophic factor receptor RET: structure, cell biology, inherited diseases","volume":"39","author":"Runeberg-Roos","year":"2007","journal-title":"Ann. Med."},{"key":"10.1016\/j.nbd.2016.07.008_bb0165","doi-asserted-by":"crossref","first-page":"4077","DOI":"10.1242\/dev.124.20.4077","article-title":"Glial-cell-line-derived neurotrophic factor is required for bud initiation from ureteric epithelium","volume":"124","author":"Sainio","year":"1997","journal-title":"Development"},{"key":"10.1016\/j.nbd.2016.07.008_bb0170","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.expneurol.2006.07.015","article-title":"Point source concentration of GDNF may explain failure of phase II clinical trial","volume":"202","author":"Salvatore","year":"2006","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.nbd.2016.07.008_bb0175","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3171\/jns.2005.102.2.0216","article-title":"Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor","volume":"102","author":"Slevin","year":"2005","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.nbd.2016.07.008_bb0180","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/j.1460-9568.1993.tb00526.x","article-title":"Widespread and developmentally regulated expression of neurotrophin-4 mRNA in rat brain and peripheral tissues","volume":"5","author":"Timmusk","year":"1993","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.nbd.2016.07.008_bb0185","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1042\/BJ20041257","article-title":"The first cysteine-rich domain of the receptor GFRalpha1 stabilizes the binding of GDNF","volume":"387","author":"Virtanen","year":"2005","journal-title":"Biochem. J."},{"key":"10.1016\/j.nbd.2016.07.008_bb0190","doi-asserted-by":"crossref","first-page":"9651","DOI":"10.1523\/JNEUROSCI.0833-09.2009","article-title":"Mesencephalic astrocyte-derived neurotrophic factor is neurorestorative in rat model of Parkinson's disease","volume":"29","author":"Voutilainen","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2016.07.008_bb0195","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jneumeth.2008.08.027","article-title":"Striatal volume differences between non-human and human primates","volume":"176","author":"Yin","year":"2009","journal-title":"J. Neurosci. Methods"}],"container-title":["Neurobiology of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096999611630167X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096999611630167X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,3]],"date-time":"2022-07-03T05:16:07Z","timestamp":1656825367000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096999611630167X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":39,"alternative-id":["S096999611630167X"],"URL":"https:\/\/doi.org\/10.1016\/j.nbd.2016.07.008","relation":{},"ISSN":["0969-9961"],"issn-type":[{"value":"0969-9961","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Developing therapeutically more efficient Neurturin variants for treatment of Parkinson's disease","name":"articletitle","label":"Article Title"},{"value":"Neurobiology of Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nbd.2016.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}